(0.00%) 5 331.50 points
(0.01%) 39 949 points
(-0.11%) 18 742 points
(-0.80%) $79.16
(0.58%) $2.77
(-0.71%) $2 421.30
(-1.67%) $31.89
(-1.40%) $1 048.80
(-0.11%) $0.920
(-0.47%) $10.65
(-0.08%) $0.786
(-0.31%) $90.40
Live Chart Being Loaded With Signals
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States...
Stats | |
---|---|
Šios dienos apimtis | 45 075.00 |
Vidutinė apimtis | 129 970 |
Rinkos kapitalizacija | 88.92M |
EPS | $0 ( 2024-05-14 ) |
Kita pelno data | ( $-0.770 ) 2024-08-02 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.0400 |
ATR14 | $0.0530 (0.42%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-05-08 | Amoroso Michael | Buy | 8 334 | Common Stock |
2024-05-08 | Kelly John Alexander | Buy | 8 334 | Common Stock |
2024-05-08 | Smith J. Jefferson | Buy | 833 | Common Stock |
2024-05-08 | Scimeca Dario | Buy | 833 | Common Stock |
2024-05-04 | Pire Shari Lisa | Buy | 4 202 | Common Stock |
INSIDER POWER |
---|
14.40 |
Last 100 transactions |
Buy: 2 573 781 | Sell: 1 742 339 |
Tūris Koreliacija
Precision BioSciences Inc Koreliacija
10 Labiausiai teigiamai susiję koreliacijos |
---|
10 Labiausiai neigiamai susiję koreliacijos |
---|
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Precision BioSciences Inc Koreliacija - Valiuta/Žaliavos
Precision BioSciences Inc Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $48.73M |
Bruto pelnas: | $40.47M (83.06 %) |
EPS: | $-18.16 |
FY | 2023 |
Pajamos: | $48.73M |
Bruto pelnas: | $40.47M (83.06 %) |
EPS: | $-18.16 |
FY | 2022 |
Pajamos: | $25.10M |
Bruto pelnas: | $16.09M (64.12 %) |
EPS: | $-41.95 |
FY | 2021 |
Pajamos: | $115.53M |
Bruto pelnas: | $0.00 (0.00 %) |
EPS: | $-0.520 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Precision BioSciences Inc
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to recognize and kill cancer cells; PBCAR0191, which is in Phase 1/2a clinical trial in adult patients with R/R NHL or R/R B-cell precursor acute lymphoblastic leukemia, or B-ALL; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T immunotherapy targeting BCMA for the treatment of R/R multiple myeloma. The company has development and commercial license agreement with Les Laboratoires Servier to develop allogeneic chimeric antigen receptor T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; Tiziana Life Sciences to evaluate foralumab, a fully human anti-CD3 monoclonal antibody as a lymphodepleting agent for the potential treatment of cancers; and iECURE, Inc. to develop ARCUS-based gene editing therapies. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.